Development and evaluation of a new Plasmodium falciparum 3D7 blood stage malaria cell bank for use in malaria volunteer infection studies
Stephen D Woolley, Melissa Fernandez, Maria Rebelo, Stacey A Llewellyn, Louise Marquart, Fiona H Amante, Helen E Jennings, Rebecca Webster, Katharine Trenholme, Stephan Chalon, Joerg J Moehrle, James S McCarthy, Bridget E Barber
MALARIA JOURNAL | BMC | Published : 2021
BACKGROUND: New anti-malarial therapeutics are required to counter the threat of increasing drug resistance. Malaria volunteer infection studies (VIS), particularly the induced blood stage malaria (IBSM) model, play a key role in accelerating anti-malarial drug development. Supply of the reference 3D7-V2 Plasmodium falciparum malaria cell bank (MCB) is limited. This study aimed to develop a new MCB, and compare the safety and infectivity of this MCB with the existing 3D7-V2 MCB, in a VIS. A second bank (3D7-V1) developed in 1995 was also evaluated. METHODS: The 3D7-V2 MCB was expanded in vitro using a bioreactor to produce a new MCB designated 3D7-MBE-008. This bank and 3D7-V1 were then eval..View full abstract
Awarded by Medicines for Malaria Venture by the Bill and Melinda Gates Foundation
Awarded by National Health and Medical Research Council of Australia (NHMRC) program Grant
QIMR Berghofer Medical Research Institute sponsored the studies, with support from Medicines for Malaria Venture, through funds provided by the Bill and Melinda Gates Foundation (Grant OPP1111147). JSM received funding from a National Health and Medical Research Council of Australia (NHMRC) program Grant (1132975). JSM is also supported by a NHMRC Practitioner Fellowship.